Tilray Expands Medical Cannabis Footprint in Europe
NEW YORK, Oct. 26, 2021 – PRESS RELEASE – Tilray Inc., a global pioneer in medical cannabis research, cultivation, production and distribution, announced it has been selected by the Luxembourg Ministry of Health as a supplier of Good Manufacturing Practice (GMP) certified medical cannabis products for the country’s medical cannabis program.
Following this selection, Tilray will supply a variety of its pharmaceutical-grade medical cannabis products, including extracts and dried flower with different degrees of THC and CBD for patients with varying medical conditions. These prescription-based medical cannabis products will be administered to qualifying patients in Luxembourg under the supervision of physicians.
Tilray Chairman and CEO Irwin D. Simon said, “We believe that Tilray’s growth potential in the European Union represents a $1 billion opportunity, and today’s announcement affirms that we are turning potential into performance. With today’s validation from the Luxembourg Ministry of Health, Tilray now offers branded medical cannabis in 20 countries around the world—a testament to our high standards and status as a trusted partner to patients in need. We’re proud to be building this unrivaled global platform and will continue to advocate for patient access in Europe and countries around the world.”
Denise Faltischek, head of international and chief strategy officer, added, “Tilray’s mission includes an unwavering conviction that patients around the world should have access to safe, high-quality, cannabinoid-based medicine. We’re proud to expand this effort to Luxembourg and provide patients in need with pharmaceutical-grade medical cannabis products. We are committed to being a trusted partner, and we will continue to leverage our strong medical platform to increase access to the highest-quality medical cannabis for patients worldwide.”
Tilray operates two state-of-the-art GMP-certified cannabis cultivation facilities in Europe located in Cantanhede, Portugal, and Neumunster, Germany. The EU campus in Portugal is a multifaceted production facility that includes the cultivation, extraction, processing and packaging of medical cannabis. It also serves as a hub supporting Tilray’s clinical research and product development efforts across Europe.
In addition, Tilray has established sales and distribution arrangements to supply medical cannabis through major pharmaceutical distribution channels, including CC Pharma, throughout Germany and the EU, which will serve as a means to allowing patients to access Tilray’s GMP-certified finished medical cannabis.